Darolutamide Improves OS in Metastatic Prostate Cancer
Darolutamide (Nubeqa) combined with standard treatment significantly improved survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), the phase III ARASENS trial found. At data cutoff, patients who received darolutamide plus androgen deprivation therapy (ADT) and docetaxel had a 32.5% lower risk of death compared with the group who received placebo plus the standard (HR […]
Darolutamide Tied to Symptom Control in Non-Metastatic Prostate Cancer
Darolutamide (Nubeqa) was linked with a decrease in locally invasive procedures, as well as local urinary and bowel symptoms, in patients with nonmetastatic (nm) castration-resistant prostate cancer (CRPC), according to analysis of the ARAMIS trial. The drug, compared with placebo, was also associated with a delayed deterioration in patient quality of life (QoL) related to […]